80 Entecavir results in continued virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in lamivudine-refractory, HBeAg(+) chronic hepatitis B patients (ETV-026)

Authors:
  • CYC. Yurdaydin
    C. Yurdaydin
  • JSJ. Sollano
    J. Sollano
  • SHS. Hadziyannis
    S. Hadziyannis
  • SKS. Kaymakoglu
    S. Kaymakoglu
  • MSM. Sherman
    M. Sherman
  • HBH. Brett-Smith
    H. Brett-Smith
  • JVJ. Vaughan
    J. Vaughan
  • RHR.G. Hindes
    R.G. Hindes
Publisher website
Google Scholar
Abstract
No abstract available